Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

57.73 +0.95 (+1.68%)
Streaming Delayed Price Updated: 12:48 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Royalty Pharma reports second quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma declares third quarter 2026 dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma reports first quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Second Quarter 2026 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Expansion of Leadership Team
Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Reports Q4 and Full Year 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Reports Third Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.